MedTrace Logo

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

NCT02479139 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2017-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to establish the therapeutic range of ANT-1207 in the treatment of primary axillary hyperhidrosis.

Conditions

  • Hyperhidrosis

Interventions

BIOLOGICAL

Vehicle

Vehicle for ANT-1207 liniment formulation without active ingredient.

BIOLOGICAL

ANT-1207

Botulinum toxin Type A topical liniment (ANT-1207).

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Joan-En Lin · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-03
Primary Completion
2016-02-29
Completion
2016-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479139 on ClinicalTrials.gov